NeuroBasic Profile — 24 Hour Urine
The NeuroBasic Profile is a 24-hour urine panel measuring nine urinary neurotransmitters and neuroactive amines — serotonin, dopamine, norepinephrine, epinephrine, GABA, glutamate, glycine, β-phenylethylamine, and histamine — to assess peripheral neurotransmitter synthesis capacity and relative balance, guiding amino acid precursor supplementation and nutritional intervention in functional and integrative medicine practice. Results reflect peripheral and enteric production rather than central nervous system neurotransmitter activity directly.
9
Biomarkers
Urine (24-hour collection)
Sample
7–10 business days
Turnaround
No — however, a specific dietary restriction protocol is required for 48–72 hours prior to and during the collection period. Patients must avoid bananas, pineapple, avocados, walnuts, chocolate, vanilla, tomatoes, fermented foods, caffeine, and alcohol. # REVIEWER FLAG: Confirm Doctor's Data's exact dietary restriction list and protocol timing from their collection kit instructions before publication.
Fasting
What is the NeuroBasic Profile test?
The NeuroBasic Profile measures nine urinary neurotransmitters and neuroactive amines — serotonin, dopamine, norepinephrine, epinephrine, GABA, glutamate, glycine, β-phenylethylamine, and histamine — via 24-hour urine collection. The 24-hour collection window provides an integrated measure of neurotransmitter synthesis and excretion across the full diurnal cycle, capturing physiological variation that single-spot urine samples would miss. Results are used in functional and integrative medicine to characterise neurotransmitter synthesis capacity, assess relative inhibitory and excitatory balance, identify potential precursor and cofactor deficiencies, and guide targeted amino acid supplementation protocols. A critical interpretive context applies to this test that practitioners must communicate to patients and document in clinical records: urinary neurotransmitter levels predominantly reflect peripheral and enteric neurotransmitter production rather than central nervous system neurotransmission. The majority of urinary serotonin derives from enterochromaffin cells in the gastrointestinal tract; urinary catecholamines reflect peripheral sympathetic and adrenomedullary output; urinary GABA and glutamate reflect peripheral metabolic activity rather than central inhibitory-excitatory balance. The NeuroBasic Profile is not validated as a diagnostic tool for psychiatric conditions by mainstream clinical psychiatry or laboratory medicine guidelines, and results should not be used to diagnose depressive disorder, anxiety disorders, ADHD, or other DSM-defined conditions in isolation. Its clinical utility lies in guiding functional and nutritional interventions — amino acid precursor therapy, cofactor supplementation, and dietary modification — within an integrative clinical framework, where practitioners interpret findings alongside a comprehensive clinical history, dietary assessment, and validated psychometric instruments.
What does the NeuroBasic Profile test measure?
Serotonin is synthesised from dietary tryptophan via hydroxylation to 5-hydroxytryptophan (5-HTP) and subsequent decarboxylation. Approximately 90–95% of the body's total serotonin is produced in enterochromaffin cells of the gastrointestinal mucosa, with the remaining 5–10% synthesised in the raphe nuclei of the brainstem. Urinary serotonin therefore predominantly reflects peripheral and enteric production rather than central serotonergic neurotransmission. It is catabolised by monoamine oxidase (MAO) to 5-hydroxyindoleacetic acid (5-HIAA), which is the principal urinary metabolite.
Urinary serotonin measurement in the functional medicine context is used to assess serotonin synthesis capacity as a surrogate for tryptophan availability and cofactor sufficiency (pyridoxal-5-phosphate, iron, zinc). Reduced levels may reflect precursor depletion, malabsorption, or impaired enteric synthesis and are used to guide amino acid supplementation with L-tryptophan or 5-HTP. Practitioners should note that urinary levels do not directly reflect CNS serotonin activity — interpretation as a proxy for brain serotonergic tone requires clinical correlation and is not validated by mainstream psychiatry.
Dopamine is synthesised from L-tyrosine via L-DOPA through the sequential actions of tyrosine hydroxylase and DOPA decarboxylase. In urine, dopamine derives from renal tubular cells (which synthesise and excrete dopamine locally), peripheral sympathetic neurons, the adrenal medulla, and intestinal enteroendocrine cells. Central dopaminergic neurons contribute negligibly to urinary dopamine levels given the blood-brain barrier. Dopamine is catabolised to homovanillic acid (HVA) via COMT and MAO pathways.
Urinary dopamine is used in functional medicine assessments of dopaminergic activity, motivation, and focus, and as a guide for amino acid precursor therapy with L-tyrosine or L-phenylalanine. Elevated levels are clinically relevant in the investigation of catecholamine-secreting tumours (phaeochromocytoma, paraganglioma), where 24-hour urine catecholamines are a standard diagnostic tool. Practitioners should recognise that urinary dopamine reflects peripheral production and is not a validated surrogate for mesolimbic or nigrostriatal dopaminergic neurotransmission.
Norepinephrine is synthesised from dopamine by dopamine β-hydroxylase within sympathetic nerve terminals and the adrenal medulla. Urinary norepinephrine derives predominantly from peripheral sympathetic nervous system spillover into the circulation and renal excretion; central noradrenergic neurons contribute minimally to urinary output. It is the primary catecholamine of sympathetic fight-or-flight activation and is catabolised by MAO and COMT to normetanephrine and vanillylmandelic acid (VMA).
In functional medicine, urinary norepinephrine is assessed alongside epinephrine as an indicator of sympathetic nervous system tone and adrenal-sympathetic output, particularly in the context of chronic stress, dysautonomia, and HPA axis dysregulation. Markedly elevated levels warrant clinical exclusion of catecholamine-secreting tumours before functional interpretations are applied. Reduced levels in the context of chronic fatigue are interpreted as sympathoadrenal depletion, guiding precursor support.
Epinephrine is synthesised exclusively in the adrenal medulla from norepinephrine by phenylethanolamine-N-methyltransferase (PNMT), a reaction induced by high local cortisol concentrations from the adrenal cortex. Its urinary output reflects adrenomedullary secretory activity rather than peripheral sympathetic neuronal function, distinguishing it mechanistically from norepinephrine in clinical interpretation.
Urinary epinephrine is assessed as a direct marker of adrenomedullary output. In functional medicine, chronically suppressed epinephrine output alongside low norepinephrine is interpreted as evidence of adrenal medullary depletion in the context of prolonged sympathetic activation. As with norepinephrine, significantly elevated values warrant formal investigation to exclude phaeochromocytoma before functional interpretations are applied.
GABA is the primary inhibitory neurotransmitter of the central nervous system, synthesised from glutamate by glutamic acid decarboxylase (GAD) — a reaction requiring pyridoxal-5-phosphate (vitamin B6) as an essential cofactor. Urinary GABA is derived from peripheral sources including the pancreas, gastrointestinal tract, and renal tubular cells; central GABAergic neurons do not contribute measurably to urinary output due to blood-brain barrier exclusion.
In functional medicine, urinary GABA is used alongside urinary glutamate as a proxy for the balance between inhibitory and excitatory neurotransmitter tone. Reduced GABA output is associated with anxiety, sleep disturbance, and seizure susceptibility in integrative clinical frameworks and guides supplementation with GABA precursors, magnesium, taurine, and B6. Practitioners must note that peripheral urinary GABA does not directly reflect central GABAergic inhibitory activity — the blood-brain barrier prevents GABA from entering the CNS when supplemented orally, complicating direct interpretation.
Glutamate is the primary excitatory neurotransmitter of the central nervous system and is also central to nitrogen metabolism, protein synthesis, and the urea cycle peripherally. Urinary glutamate is derived largely from renal tubular metabolism and dietary protein catabolism rather than central glutamatergic neurotransmission. It serves as the direct biosynthetic precursor to GABA via glutamic acid decarboxylase.
In functional medicine, urinary glutamate is interpreted in the context of the inhibitory/excitatory balance alongside GABA. Disproportionately elevated urinary glutamate relative to GABA is associated in integrative frameworks with excitatory neurological symptoms, sensitivity reactions, and poor stress tolerance. Pyridoxal-5-phosphate (B6) deficiency impairs conversion of glutamate to GABA, producing elevated glutamate output that is considered a cofactor deficiency signal in this context.
Glycine serves dual roles as an inhibitory neurotransmitter — acting at glycine receptors in the spinal cord and brainstem — and as a major component of collagen, glutathione synthesis, and one-carbon metabolism. Urinary glycine reflects a combination of protein catabolism, hepatic glycine conjugation, and renal tubular handling rather than central glycinergic neurotransmission directly.
In functional medicine frameworks, urinary glycine is assessed as a marker of glycine availability for neurotransmitter and metabolic functions. Low glycine output may suggest depleted reserves affecting inhibitory neurotransmission, collagen synthesis, and glutathione production. It is used to guide glycine supplementation in protocols addressing sleep quality, spasticity, and oxidative stress support.
β-Phenylethylamine is a trace amine synthesised from L-phenylalanine by aromatic L-amino acid decarboxylase. It acts as an endogenous neuromodulator and trace amine-associated receptor 1 (TAAR1) agonist, stimulating monoamine release and synaptic dopamine availability. PEA has an extremely short half-life (minutes) due to rapid MAO-B catabolism to phenylacetic acid, making urinary levels a reflection of both synthesis rate and MAO-B activity.
Urinary PEA is assessed in functional medicine as a marker of endogenous trace amine activity, with reduced levels associated with depression, attention dysregulation, and motivational impairment in integrative frameworks. Elevated PEA has been associated with schizophrenia spectrum conditions in research contexts. Phenylacetic acid (the primary PEA metabolite) is sometimes measured alongside PEA to assess the synthesis-to-catabolism ratio. # REVIEWER FLAG: PEA clinical interpretation has a limited mainstream evidence base — reviewer to assess whether interpretive claims require additional caveating.
Histamine is synthesised from L-histidine by histidine decarboxylase in mast cells, basophils, enterochromaffin-like cells of the gastric mucosa, and intestinal bacteria. Urinary histamine reflects peripheral histamine production and catabolism — the gut microbiome and dietary histamine load are the dominant determinants of urinary output, with central histaminergic neurotransmission contributing minimally.
Urinary histamine is included in the NeuroBasic Profile as a neuroactive amine with relevance to neuroinflammation, sleep-wake regulation, and immune activation. In functional medicine, elevated urinary histamine is interpreted in the context of histamine intolerance, mast cell activation, and gut dysbiosis. Dietary high-histamine foods and DAO (diamine oxidase) deficiency are primary drivers of elevated urinary histamine and must be considered in result interpretation.
Why is the NeuroBasic Profile test ordered?
- Functional and integrative medicine practitioners assessing neurotransmitter synthesis capacity to guide amino acid precursor therapy (L-tryptophan, 5-HTP, L-tyrosine, L-phenylalanine) in patients with mood disturbance, anxiety, fatigue, or sleep dysregulation
- Investigation of potential serotonin or catecholamine precursor depletion in patients on long-term SSRIs or SNRIs, where pharmacological reuptake inhibition may be masking underlying synthesis insufficiency # REVIEWER FLAG: This clinical application is used in integrative practice but is not supported by mainstream psychiatric guidelines — reviewer to consider appropriate framing
- Chronic fatigue and HPA axis dysregulation workup — assessment of sympathoadrenal catecholamine output (norepinephrine, epinephrine) alongside adrenal function panels
- Attention and executive function concerns — dopamine and PEA profile assessment as part of a functional workup in patients with ADHD-spectrum symptoms, interpreted alongside clinical assessment
- Anxiety and sleep disturbance — GABA:glutamate balance and serotonin assessment to guide inhibitory neurotransmitter support protocols
- Histamine intolerance and mast cell activation investigation — urinary histamine as one component of a broader assessment including DAO enzyme activity and dietary elimination
- Gut-brain axis evaluation — serotonin and GABA output as functional markers of enteric neurotransmitter synthesis in patients with concurrent gastrointestinal and neurological or mood symptoms
- Monitoring response to neurotransmitter support protocols — repeat testing following amino acid precursor supplementation to assess changes in synthesis output against baseline
Sample collection and turnaround
Sample type
Urine (24-hour collection)
Fasting required
No — however, a specific dietary restriction protocol is required for 48–72 hours prior to and during the collection period. Patients must avoid bananas, pineapple, avocados, walnuts, chocolate, vanilla, tomatoes, fermented foods, caffeine, and alcohol. # REVIEWER FLAG: Confirm Doctor's Data's exact dietary restriction list and protocol timing from their collection kit instructions before publication.
Collection method
24-hour urine collection using Doctor's Data collection kit — phlebotomy is not required; this is a urine-only specimen
Turnaround
7–10 business days
Collection notes
Patient discards the first morning void on Day 1, then collects all subsequent urine including the first morning void of Day 2 into the Doctor's Data collection container. The container must be kept refrigerated throughout the collection period. Vigorous physical exercise and acute psychological stress should be avoided during collection. All psychotropic and neurologically active medications should be documented on the requisition form; the clinical decision to withhold medications through collection must be made by the patient's prescribing clinician and is outside the scope of the laboratory. Specimen must be delivered to the designated shipping point promptly following collection completion and shipped according to Doctor's Data cold-chain instructions. # REVIEWER FLAG: Confirm exact collection container type (preservative-free or acid-preserved), refrigeration requirements, and shipping cold-chain protocol from Doctor's Data collection kit instructions before publication.
Specimen requirements
Total 24-hour urine volume required; minimum aliquot per Doctor's Data assay specification. Total volume must be recorded on the requisition form for accurate per-24-hour calculation of analyte totals. Specimen must be refrigerated during collection and shipped cold. # REVIEWER FLAG: Confirm minimum aliquot volume and shipping temperature requirements with Doctor's Data.
What can affect NeuroBasic Profile results?
Bananas, pineapple, avocados, walnuts, chocolate, vanilla, tomatoes, and fermented foods are high in serotonin, dopamine precursors, or histamine and can significantly elevate corresponding urinary analytes independent of endogenous synthesis status. A dietary restriction protocol — typically 48–72 hours prior to and during collection — is required for meaningful results. # REVIEWER FLAG: Confirm Doctor's Data dietary restriction protocol and specific food exclusion list from their collection instructions.
Caffeine and other xanthine stimulants activate the sympathoadrenal axis, increasing norepinephrine and epinephrine output acutely. Caffeinated beverages should be avoided during the collection period; practitioners should document habitual caffeine use when interpreting catecholamine results.
Medications affecting monoamine reuptake, synthesis, or catabolism will directly and substantially alter urinary neurotransmitter profiles. MAO inhibitors markedly elevate catecholamines and serotonin by blocking catabolism; SSRIs and SNRIs affect reuptake without directly altering synthesis but may influence overall turnover; stimulants increase catecholamine release and turnover. Current medications must be documented and results interpreted accordingly — the clinical decision to withhold or continue medications through collection should be discussed with the patient's prescribing clinician.
Acute physical exertion and psychological stress activate the sympathoadrenal axis, elevating urinary norepinephrine and epinephrine. Strenuous activity should be avoided during the 24-hour collection period and documented if it occurs.
Under-collection — most commonly due to a missed void or failure to collect the final specimen — artificially reduces all 24-hour totals proportionally. Creatinine excretion is used as an internal reference to detect under-collection; a 24-hour creatinine below expected range for the patient's age, sex, and body mass is a flag for inadequate collection requiring repeat testing.
Enteric bacteria are major contributors to peripheral serotonin and GABA synthesis via the gut-brain axis. Dysbiosis — from antibiotic exposure, gastrointestinal pathology, or dietary disruption — can alter urinary serotonin, GABA, and histamine output independent of neurological status, representing a significant confounding variable in result interpretation.
What do NeuroBasic Profile results mean?
Elevated
Elevated individual analytes require pattern-based interpretation rather than isolated assessment. Elevated catecholamines (norepinephrine, epinephrine) may indicate acute sympathoadrenal activation, chronic stress response, or — at markedly high levels — catecholamine-secreting tumour requiring formal clinical investigation. Elevated serotonin may reflect recent high-tryptophan diet, exogenous 5-HTP supplementation, or rarely carcinoid tumour — clinical context and dietary history are essential. Elevated histamine points to dietary histamine load, DAO deficiency, or mast cell hyperactivation. Elevated glutamate relative to GABA suggests inhibitory-excitatory imbalance that integrative protocols address with B6, magnesium, and taurine support.
Normal
Results within the Doctor's Data reference ranges for all analytes indicate adequate peripheral neurotransmitter production within the tested window. In patients with active neuropsychiatric symptoms and a normal profile, the results should not be used to dismiss clinical findings — central neurotransmitter dysregulation, receptor sensitivity changes, and transport abnormalities are not captured by peripheral urinary measurement.
Reduced
Reduced catecholamines — particularly norepinephrine and epinephrine — may reflect sympathoadrenal depletion in the context of chronic stress and are interpreted as indicating a need for tyrosine or phenylalanine precursor support. Reduced serotonin may indicate tryptophan depletion or deficiency of synthesis cofactors (B6, iron, zinc) and guides 5-HTP or L-tryptophan supplementation. Reduced GABA alongside elevated glutamate is interpreted as evidence of inhibitory insufficiency. Reduced PEA may reflect increased MAO-B catabolism or low phenylethylamine synthesis from phenylalanine.
Note: The most important interpretive caveat for this panel is the dissociation between urinary neurotransmitter output and central nervous system neurotransmitter activity. Clinicians trained in mainstream laboratory medicine should note that the correlation between urinary serotonin and central serotonergic tone, or urinary GABA and central inhibitory function, is not established by high-quality clinical evidence. This panel is best positioned as a functional supplement to clinical assessment rather than a standalone diagnostic tool. All results require integration with detailed dietary history, medication review, collection adequacy assessment (via creatinine), and validated clinical instruments. The interpretive framework used for amino acid precursor guidance derives from functional medicine practice and does not carry the same level of evidence validation as mainstream clinical chemistry applications.
Frequently asked questions
The NeuroBasic Profile measures nine urinary neurotransmitters and neuroactive amines — serotonin, dopamine, norepinephrine, epinephrine, GABA, glutamate, glycine, β-phenylethylamine, and histamine — excreted over a 24-hour period. Results reflect peripheral and enteric neurotransmitter production rather than central nervous system activity directly, and are used to assess synthesis capacity and guide amino acid precursor therapy.
How to access the NeuroBasic Profile test
The NeuroBasic Profile reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: May 22, 2026
Last reviewed: May 22, 2026
- Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological dependence on plasma tryptophan levels. Science. (1971)
- Goldstein DS. Catecholamines 101. Clin Auton Res. (2010)
- Hinz M, Stein A, Uncini T. 5-HTP efficacy and contraindications. Neuropsychiatr Dis Treat. (2012)
- Sudo N, et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. (2004)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.